• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Abscess - Pipeline Review, H2 2012 Product Image

Abscess - Pipeline Review, H2 2012

  • Published: September 2012
  • 43 pages
  • Global Markets Direct

Abscess – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Abscess - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Abscess, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abscess. Abscess - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Abscess.
- A review of the Abscess products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Abscess Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Abscess 7
Abscess Therapeutics under Development by Companies 9
Abscess Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Abscess Therapeutics – Products under Development by Companies 13
Abscess Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Abscess Therapeutics Development 15
Taiho Pharmaceutical Co., Ltd. 15
Trius Therapeutics, Inc. 16
Durata Therapeutics Inc. 17
Abscess – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
dalbavancin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
torezolid - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Tissue plasminogen activator - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
JNJ-Q2 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
pasireotide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Moxifloxacin + Metronidazole - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Trimethoprim + Sulfamethoxazole + Clindamycin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
YP-18 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Abscess Therapeutics – Drug Profile Updates 36
Abscess Therapeutics - Dormant Products 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products Under Development for Abscess, H2 2012 7
Products under Development for Abscess – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Taiho Pharmaceutical Co., Ltd., H2 2012 15
Trius Therapeutics, Inc., H2 2012 16
Durata Therapeutics Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Abscess Therapeutics – Drug Profile Updates 36
Abscess Therapeutics – Dormant Products 41

List of Figures
Number of Products under Development for Abscess, H2 2012 7
Products under Development for Abscess – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos